research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-09. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
In mammals, the genome only contains one gene for tropoelastin, called ELN. The human ELN gene is a 45 kb segment on chromosome 7, and has 34 exons interrupted by almost 700 introns, with the first exon being a signal peptide assigning its extracellular localization. The large number of introns suggests that genetic recombination may contribute to the instability of the gene, leading to diseases such as SVAS. The expression of tropoelastin mRNA is highly regulated under at least eight different transcription start sites. Tissue specific variants of elastin are produced by alternative splicing of the tropoelastin gene. There are at least 11 known human tropoelastin isoforms. These isoforms are under developmental regulation, however there are minimal differences among tissues at the same developmental stage.
=== Persian period === In 537–520 BCE, Zerubbabel became Yehud's governor and started work on the Second Temple, which was stopped. In 520–516 BCE, Haggai and Zechariah goaded the Judahites to resume work on the Temple. Upon completion, Joshua became its high priest. In 458–433 BCE, Ezra and Nehemiah led another group of Judahites to Yehud, with Artaxerxes's permission. Nehemiah rebuilt the temple after some unspecified disaster and removed foreign influence from the Judahite community. That said, some Judahites elected to stay in Persia, where they almost faced annihilation. This period is covered by the entirety of the Book of Ezra, Book of Nehemiah, the Book of Esther, the Book of Haggai, the Book of Zechariah, and the Book of Malachi.
The Meeting of Teano between Garibaldi and King Victor Emmanuel II of Savoy took place on 26 October 1860, where he annexed Mezzogiorno. On 19 August 1860, Calabria was invaded from Sicily by Giuseppe Garibaldi and his Redshirts as part of the Expedition of the Thousand. Through King Francesco II of Naples had dispatched 16,000 soldiers to stop the Redshirts, who numbered about 3,500, after a token battle at Reggio Calabria won by the Redshirts, all resistance ceased and Garibaldi was welcomed as a liberator from the oppressive rule of the Bourbons wherever he went in Calabria. Calabria together with the rest of the Kingdom of Naples was incorporated in 1861 into the Kingdom of Italy. Garibaldi planned to complete the Risorgimento by invading Rome, still ruled by the pope protected by a French garrison, and began with semi-official encouragement to raise an army. Subsequently, King Victor Emmanuel II decided the possibility of war with France was too dangerous, and on 29 August 1862 Garibaldi's base in the Calabrian town of Aspromonte was attacked by the Regio Esercito. The Battle of Aspromonte ended with the Redshirts defeated with several being executed after surrendering while Garibaldi was badly wounded. With the plebiscite of 21 October 1860, Calabria and the other southern provinces became part of the Kingdom of Sardinia: consequently, elections were called to allow the newly annexed territories to select representation in Parliament. The election was held on 27 January 1861, and the new Parliament was inaugurated in Turin on February 18.
In the 1826 General Convention of Friendship, Commerce and Navigation with the king of Denmark, the United States recognised Greenland as a northern possession of the king, and accepted the trade restrictions that Denmark imposed there. In the Treaty of the Danish West Indies, signed in 1916, the US government explicitly recognised Danish sovereignty over all of Greenland. In the 1941 US–Danish agreement, the American Government "reiterate[d] its recognition of and respect for the sovereignty of the Kingdom of Denmark over Greenland". During World War II, the United States defended Greenland at the request of Danish and Greenlandic officials acting without approval from the central government of Denmark, while it was under Nazi occupation. In the 1951 Greenland Defense Agreement, the United States again recognised the sovereignty of the Kingdom of Denmark over all of Greenland. In the 2004 amendment to the Greenland Defense Agreement, the United States recognised Greenland as "an equal part of the Kingdom of Denmark under the Constitution [with] a wide ranging Greenland Home Rule".
Sources: en.wikipedia.org
=== Mid-infrared === With the advent of cheap microcomputers it became possible to have a computer dedicated to controlling the spectrometer, collecting the data, doing the Fourier transform and presenting the spectrum. This provided the impetus for the development of FTIR spectrometers for the rock-salt region. The problems of manufacturing ultra-high precision optical and mechanical components had to be solved. A wide range of instruments are now available commercially. Although instrument design has become more sophisticated, the basic principles remain the same. Nowadays, the moving mirror of the interferometer moves at a constant velocity, and sampling of the interferogram is triggered by finding zero-crossings in the fringes of a secondary interferometer lit by a helium–neon laser. In modern FTIR systems the constant mirror velocity is not strictly required, as long as the laser fringes and the original interferogram are recorded simultaneously with higher sampling rate and then re-interpolated on a constant grid, as pioneered by James W. Brault. This confers very high wavenumber accuracy on the resulting infrared spectrum and avoids wavenumber calibration errors.
Increased blood CRP levels were higher in people with avian flu H7N9 compared to those with H1N1 (more common) influenza, with a review reporting that severe H1N1 influenza had elevated CRP. In 2020, people infected with COVID-19 in Wuhan, China, had elevated CRP. MedlinePlus Encyclopedia: C-reactive protein Inflammation, Heart Disease and Stroke: The Role of C-Reactive Protein (American Heart Association) C-Reactive+Protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) CRP: analyte monograph - The Association for Clinical Biochemistry and Laboratory Medicine George Vrousgos, N.D. - Southern Cross University Archived 2020-02-18 at the Wayback Machine Human CRP genome location and CRP gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P02741 (C-reactive protein) at the PDBe-KB.
== Availability == Chlordiazepoxide is available in various dosage forms, alone or in combination with other drugs, worldwide. In combination with clidinium as NORMAXIN-CC and in combination with dicycloverine as NORMAXIN for IBS, and with the tricyclic antidepressant amitriptyline as Limbitrol.
== Unicode == Unicode uses the (Modern Greek-based) spelling "lamda" in character names, instead of "lambda", due to "the pre-existing names in ISO 8859-7, as well as preferences expressed by the Greek National Body". Latin versions of lambda were added to Unicode in 2024 for the Salishan and Wakashan languages in Canada.
== Fourth round proper == The draw for the fourth round was made on 8 January 2023, consisting of the 32 winners from the previous round. The round included one team from the fifth tier, the lowest-ranked team remaining in the competition: Wrexham.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.